BIO STATEMENT ON FDA COMMISSIONER NOMINATION

WASHINGTON, D.C. (September 25, 2002) – Biotechnology Industry Organization (BIO) President Carl B. Feldbaum today issued the following statement regarding White House intentions to nominate Mark B. McClellan, M.D., Ph.D., for commissioner of the Food and Drug Administration, according to newspaper reports:

“We are pleased that the Bush Administration has made a selection to fill this critical FDA position, and, from Dr. McClellan’s educational background and experience in medicine, health care, and economic policy, he appears to be an exceptional candidate.

“The biotechnology industry and the nation need forceful leadership from an FDA commissioner; one who can manage the agency efficiently, demonstrate to Congress the need for additional resources, and lead the way for introduction of innovative medical technologies that will benefit millions of patients.

“We look forward to learning more about Dr. McClellan’s plans for the FDA at his Senate confirmation hearing.”

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

# # #